Anixa Biosciences (ANIX)
NASDAQ:ANIX
Want to see ANIX full AI Analyst Report?
ANIX Stock Chart & Stats
$3.16
-$0.08(-3.60%)
At close: 4:00 PM EST
$3.16
-$0.08(-3.60%)
Day’s Range― - ―
52-Week Range$2.32 - $5.46
Previous CloseN/A
Volume56.82K
Average Volume (3M)204.54K
Market Cap
$84.38M
Enterprise Value$89.17M
Total Cash (Recent Filing)$13.69M
Total Debt (Recent Filing)$184.00K
Price to Earnings (P/E)―
Beta0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,023,064
10 Day Avg. Volume193,788
30 Day Avg. Volume204,545
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)8.84
Price to Sales (P/S)0.00
P/FCF Ratio-18.69
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.91K
Enterprise Value/Ebitda-8.80
Forecast
1Y Price Target
$10.50Price Target Upside232.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual Property ExpansionThe expansion of Anixa's patent portfolio in China strengthens its competitive position and potential for future commercialization in a major market.
Innovative Cancer TreatmentsAdvancing to Phase 2 trials indicates progress in developing innovative cancer treatments, which could lead to new revenue streams if successful.
Strong Equity PositionA strong equity position provides financial stability and flexibility, allowing Anixa to invest in R&D and pursue strategic opportunities.
Bears Say
Negative Cash FlowsPersistent negative cash flows challenge liquidity and sustainability, potentially limiting the company's ability to fund ongoing operations and growth.
Revenue Generation ChallengesThe inability to generate revenue highlights operational struggles, impacting long-term financial health and necessitating successful project commercialization.
Persistent LossesOngoing losses indicate operational inefficiencies and financial instability, requiring strategic changes to achieve profitability and sustain growth.
Anixa Biosciences News
ANIX FAQ
What was Anixa Biosciences’s price range in the past 12 months?
Anixa Biosciences lowest stock price was $2.32 and its highest was $5.46 in the past 12 months.
What is Anixa Biosciences’s market cap?
Anixa Biosciences’s market cap is $84.38M.
When is Anixa Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anixa Biosciences’s earnings last quarter?
Currently, no data Available
Is Anixa Biosciences overvalued?
According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued.
Does Anixa Biosciences pay dividends?
Anixa Biosciences does not currently pay dividends.
What is Anixa Biosciences’s EPS estimate?
Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anixa Biosciences have?
Anixa Biosciences has 34,023,064 shares outstanding.
What happened to Anixa Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anixa Biosciences?
Currently, no hedge funds are holding shares in ANIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anixa Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (232.28% Upside)
$10.50 (232.28% Upside)
Blogger Sentiment
Bullish
ANIX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 26.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.40%
12-Months-Change
Fundamentals
Return on Equity
-65.55%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
Anixa Biosciences
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
ANIX Stock 12 Month Forecast
Average Price Target
$10.50
▲(232.28% Upside)
Technical Analysis
Atossa Therapeutics
―
Champions Oncology
―
OKYO Pharma Limited Sponsored ADR
―
Contineum Therapeutics, Inc. Class A
―
Actuate Therapeutics, Inc.
―
Ownership Overview
5.38% Insiders
4.82% Mutual Funds
0.51% Other Institutional Investors
85.20% Public Companies and
Individual Investors